Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bextra Meta-Analysis Affirms Safety Profile, Pfizer Tells Physicians

Executive Summary

A meta-analysis of Bextra (valdecoxib) clinical trials in osteoarthritis and rheumatoid arthritis show the agent has a lower incidence of myocardial infarctions compared to traditional NSAIDs, Pfizer maintains in Dec. 2 "medical information letters.
Advertisement

Related Content

Mobic Adds Juvenile RA Indication, Cardiovascular “Black Box” Warnings
Pfizer Celebrex Revised Labeling Adds Class Cardio Risk, Moves Safety Data
Bextra Withdrawal Will Test Pfizer’s Liability Defense Record
Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return
Bextra, Vioxx Require Stronger Warnings, Additional Study, Cmte. Finds
Pfizer Tells Doctors To Consider COX-2 Alternatives; DTC Ads Are Halted
Pfizer Elaborates On Celebrex Safety Theory: Molecule Is “Unique”
Pfizer Goes On Offense With Celebrex: TV Ads, Study Proposal Stress Safety
COX-2 Market Growth Could Be Stalled Until Release Of Long-Term Safety Data
COX-2 Market Growth Could Be Stalled Until Release Of Long-Term Safety Data

Topics

Advertisement
UsernamePublicRestriction

Register

PS045048

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel